GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead GRAIL (
NASDAQ:GRAL ) said demand for its Galleri multi-cancer early detection test has continued to grow despite recent headlines related to its NHS study, according to comments made by Aaron, who identified himself during the discussion as the company’s CFO, at a Bank of America event.
Aaron said t
Here's Why Grail Shares Popped Higher This Week The company recently reported better-than-expected results, and investors are hoping for more positive news at the end of the month.
Better Healthcare Stock to Own in a Recession: Defensive or Growth? The answer to the question might surprise many investors. It pays to be open-minded about risk.
Here's Why Grail Stock Soared Higher This Week Wall Street continues to warm to the investment proposition for this high-risk and high-reward stock.
This Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last Month GRAIL, Inc. develops blood-based cancer detection technologies for healthcare providers and individuals seeking early screening solutions.
Here's Why Grail Shares Crushed the Market This Week The company's stock received a favorable assessment from a Wall Street analyst this week.
Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity The multi-cancer early detection (MCED) company delivered some extremely bad news to investors in February, but the stock may attract risk tolerant investors now.
Here's Why Grail Stock Bounced Back 16% Today The market took a more positive view on the company's prospects today, and there's still an opportunity, however small, for the Galleri trial to prove out.
Why Grail Shares Are Plummeting A large clinical trial of the company's cancer screening test did not produce the desired result.
Here's Why Grail Stock Slumped Again Today The company continues to come under pressure after a very disappointing trial result.
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.
Here's Why Grail Stock Crashed 50% Today The top-line results from its landmark trial were not good, but there's more data to come, and it might prove more favorable for investors.
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating.
Why Grail Stock Is Sinking Friday GRAIL (
NASDAQ: GRAL ) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results.
